MagnetisMM-3: Study Of Elranatamab (PF-06863135) Monotherapy in Participants With Multiple Myeloma Who Are Refractory to at Least One PI, One IMiD and One Anti-CD38 mAb

计划入组 187 人 · 首次发布于 2020 年 12 月 2 日

MAGNETISMM-2: Study of Elranatamab (PF-06863135) in Japanese Participants With Multiple Myeloma

计划入组 4 人 · 首次发布于 2021 年 3 月 15 日

MagnetisMM-4: Umbrella Study of Elranatamab (PF-06863135) in Combination With Anti-Cancer Treatments in Multiple Myeloma

计划入组 46 人 · 首次发布于 2021 年 10 月 25 日

Oxybenzone(Meijer)

C₁₄H₁₂O₃

BE-3-3-3-3

Indole-3-carbinol

C₉H₉NO

3-D Matrix Ltd.

Japan

River 3 Renal Corp.

United States

Immuno Cure 3 Limited

NHS Scotland Approves Elranatamab and Teclistamab for Relapsed/Refractory Multiple Myeloma

Elranatamab Plus Iberdomide Combination Achieves 95.5% Response Rate in Relapsed/Refractory Multiple Myeloma

GPRC5D Emerges as Promising Target in Multiple Myeloma Clinical Trials